Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF6563 (Ethanol-Free Buprenorphine) for Neonatal Opioid Withdrawal Syndrome
NCT04104646Phase 2Terminated
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CHF6563 in neonatal opioid withdrawal syndrome (NOWS) (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Duration of Treatment up to 10 weeks. Started Dec 2020; status: terminated.
02
Drugs
CHF6563
03
Conditions
neonatal opioid withdrawal syndrome (NOWS)
Beyond the preview
Go deeper on NCT04104646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04104646.